Pernilla C. Karlsson
Karolinska Institutet
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Pernilla C. Karlsson.
Nutrition and Cancer | 2007
Annett Klinder; Pernilla C. Karlsson; Yvonne Clune; Roisin Hughes; Michael Glei; Joseph Rafter; Ian Rowland; John Kevin Collins; Beatrice L. Pool-Zobel
Abstract: The assessment of cellular effects by the aqueous phase of human feces (fecal water, FW) is a useful biomarker approach to study cancer risks and protective activities of food. In order to refine and develop the biomarker, different protocols of preparing FW were compared. Fecal waters were prepared by 3 methods: (A) direct centrifugation; (B) extraction of feces in PBS before centrifugation; and (C) centrifugation of lyophilized and reconstituted feces. Genotoxicity was determined in colon cells using the Comet assay. Selected samples were investigated for additional parameters related to carcinogenesis. Two of 7 FWs obtained by methods A and B were similarly genotoxic. Method B, however, yielded higher volumes of FW, allowing sterile filtration for long-term culture experiments. Four of 7 samples were non-genotoxic when prepared according to all 3 methods. FW from lyophilized feces and from fresh samples were equally genotoxic. FWs modulated cytotoxicity, paracellular permeability, and invasion, independent of their genotoxicity. All 3 methods of FW preparation can be used to assess genotoxicity. The higher volumes of FW obtained by preparation method B greatly enhance the perspectives of measuring different types of biological parameters and using these to disclose activities related to cancer development.
F1000Research | 2018
Hedwig Widestedt; Jasna Giesecke; Pernilla C. Karlsson; Jan G. Jakobsson
Background: Cardiac arrest requires rapid and effective handling. Huge efforts have been implemented to improve resuscitation of sudden cardiac arrest patients. Guidelines around the various parts of effective management, the chain of survival, are available. The aim of the present retrospective study was to study sudden in-hospital cardiac arrest (IHCA) and the outcomes of emergence team resuscitation in a university hospital in Sweden. Methods: The Swedish Cardiopulmonary Resuscitation Registry was used to access all reported cases of IHCA at Danderyd Hospital from 2012 through 2017. Return of spontaneous circulation (ROSC), discharge alive, 30-day mortality and Cerebral Performance Scales score (CPC) were analysed. Results: 574 patients with cardiac arrests were included in the study: 307 patients (54%) had ROSC; 195 patients (34%) were alive to be discharged from hospital; and 191 patients (33%) were still alive at day-30 after cardiac arrest. Witnessed cardiac arrests, VT/VF as initial rhythm and experiencing cardiac arrest in high monitored wards were factors associated with success. However, 53% of patients’ alive at day-30 had a none-shockable rhythm, 16% showed initially a pulseless electrical activity and 37% asystole. CPC score was available for 188 out of the 195 patients that were alive to be discharged: 96.5% of patients where data was available had a favourable neurological outcome, a CPC-score of 1 or 2 at discharge, and only 6 of these patients had a CPC-score of 3 or higher (3%). Conclusions: One third of patients with sudden IHCA were discharged from hospital and alive at day-30, a clear majority without cognitive deficit related to the cardiac arrest. High monitored care, witnessed cardiac arrest and shockable rhythm were factors associated with high success; however, more than half of surviving patients had initially a none-shockable rhythm.
The American Journal of Clinical Nutrition | 2007
Joseph Rafter; Michael Bennett; Giovanna Caderni; Yvonne Clune; Roisin Hughes; Pernilla C. Karlsson; Annett Klinder; Micheal O'Riordan; Gerald C. O'Sullivan; Beatrice L. Pool-Zobel; Gerhard Rechkemmer; Monika Roller; Ian Rowland; Maddalena Salvadori; Herbert Thijs; Jan Van Loo; Bernhard Watzl; John Kevin Collins
Journal of Nutrition | 2005
Pernilla C. Karlsson; Ulrika Huss; Andrew M. Jenner; Barry Halliwell; Lars Bohlin; Joseph Rafter
Biological & Pharmaceutical Bulletin | 2011
Lucia Renee Ruhaak; Jenny Felth; Pernilla C. Karlsson; Joseph Rafter; Robert Verpoorte; Lars Bohlin
Biological & Pharmaceutical Bulletin | 2008
Jenny Pettersson; Pernilla C. Karlsson; Young Hae Choi; Robert Verpoorte; Joseph Rafter; Lars Bohlin
Cancer Letters | 2005
Pernilla C. Karlsson; Roisin Hughes; Joseph Rafter; W. Robert Bruce
Archive | 2004
Annett Klinder; E. Gietl; Roisin Hughes; N. Jonkers; Pernilla C. Karlsson; H. McGlyn; S. Pistoli; Kieran M. Tuohy; Joseph Rafter; Ian Rowland; J. van Loo; Beatrice L. Pool-Zobel
Biological & Pharmaceutical Bulletin | 2008
Jenny Pettersson; Pernilla C. Karlsson; Ulf Göransson; Joseph Rafter; Lars Bohlin
Archive | 2005
Pernilla C. Karlsson